血清异常凝血酶原在肝细胞癌诊断中的疗效分析

Clinical value of serum abnormal prothrombin in diagnosis of hepatocellular carcinoma

摘要:

目的 探讨异常凝血酶原（PIVKA- Ⅱ）在肝细胞癌（HCC）诊断中的疗效分析。方法 收集2014 年9 月-2015 年1 月于贵州省肿瘤医院收治的HCC 患者84 例、其他恶性肿瘤患者54 例、慢性乙肝患者88 例及乙肝表面抗原阴性和肝功能正常者39 例，采用化学发光/ 酶联免疫技术检测血清PIVKA- Ⅱ和甲胎蛋白（AFP）。结果 HCC 组血清PIVKA- Ⅱ和AFP 水平高于其余各组，PIVKA- Ⅱ与AFP 联合检测用于疾病诊断的敏感性为90.50%，优于单独诊断。结论 血清PIVKA- Ⅱ的检测在HCC 的诊断中具有较高的临床价值，该项目可以作为AFP 检测的补充，两者联合检测可提高HCC 的诊断效率。

Abstract:

Objective To discuss the clinical value of serum prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) in diagnosing hepatocellular carcinoma (HCC). Methods This study recruited 84 patients with HCC, 54 patients with other malignant tumors (including lung cancer, endometrial cancer, appendix mucous adenocarcinoma, etc), 88 chronic hepatitis patients, and 39 patients with negative hepatitis B surface antigen (HBsAg) and normal liver function in Tumor Hospital of Guizhou Province from September 2014 to January 2015.The serum levels of PIVKA-II and alpha-fetoprotein (AFP) were measured by chemiluminescence enzyme technique.Their data were analyzed by SPSS17.0. Results The serum levels of PIVKA-II and AFP in the HCC group were higher than those in other groups. The combination of PIVKA-II and AFP was better than single use, the sensitivity of combination of PIVKA-II and AFP was 90.50%. Conclusions Serum PIVKA-II detection has higher clinical value for diagnosis of HCC. It can be used as a supplement to AFP detection. Joint PIVKA-II and AFP detection can improve the diagnosis efficiency of HCC.